Muscarinic M1 agonist as an inhibitor of beta-amyloid (A&bgr;40 and A&bgr;42)-synthesis

US6573276B2 · kind B2 · utility

Assignee

• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

• Christoph Hock · Küsnacht (ZH), CH
• Andreas Raschig · Biberach, DE
• Marion Wienrich · Weiterstadt, DE
• Roger Nitsch · Zumikon, CH
• Klaus Mendla · Ingelheim am Rhein, DE
• Dieter Meier · Wiesbaden, DE
• Klaus Bornemann · Ingelheim am Rhein, DE
• Cornelia Dorner-Ciossek · Ingelheim am Rhein, DE

Key dates

• Filing date: Apr 30, 2002
• Grant date: Jun 3, 2003
• Expiry date: Apr 30, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/439
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of lowering the levels of A&bgr;40, A&bgr;42 and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine, or a physiologically acceptable acid addition salt thereof, and methods of treating diseases associated with the formation of diffuse and senile plaques or A&bgr;40-, A&bgr;42- and tau-containing plaques are disclosed.